Filing Overview
QuidelOrtho Corporation filed a Form 8-K dated May 31, 2022, reporting executive compensation actions following the May 27, 2022 consummation of the business combination between Quidel Corporation and Ortho Clinical Diagnostics Holdings plc. The compensation changes became effective June 1, 2022, except where otherwise noted.
Executive Compensation Changes
| Executive | Base Salary | Target Bonus Opportunity | Equity Award |
|---|---|---|---|
| Joseph M. Busky | $550,000 | 75% of base salary | $2,000,000 |
| Michelle A. Hodges | $500,000 | No change | Not disclosed |
| Michael S. Iskra | $550,000 | 75% of base salary | $2,000,000 |
| Douglas C. Bryant | Not disclosed | Not disclosed | $1,019,000 |
Material Changes and Award Terms
- The Compensation Committee approved increases to the base salaries and target bonus opportunities of certain executive officers following the business combination.
- Mr. Bryant’s award consists of performance-based restricted stock units subject to time-based vesting and revenue and cost-synergy milestones to be approved by the Board or Compensation Committee.
- Mr. Busky’s and Mr. Iskra’s awards consist of combinations of non-qualified stock options and time-based restricted stock units, as selected by each executive. The awards vest in three annual installments on the first, second, and third anniversaries of the June 1, 2022 grant date.
Financial Metrics, Liquidity, and Outlook
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or formal guidance information. It also does not provide a broader operating outlook. The disclosed performance milestones relate to future revenue and cost synergies but do not specify the targets.
Key Investor Verification Items
- Verify the final terms, valuation, and share or option quantities underlying the disclosed equity award values.
- Review subsequent filings for the revenue and cost-synergy milestones applicable to Mr. Bryant’s performance-based award.
- Assess the potential dilution and compensation expense associated with the stock options and restricted stock units.
- Review post-combination financial filings for actual operating results, integration costs, synergies, and any changes to executive compensation.